Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches
| Autor: | Anna Vischer, Ciprian Tomuleasa, Bobe Petrushev, Horia Bumbea, Sergiu Pasca, Delia Dima, Ravnit Grewal, Sonia Cismas, Sonia Selicean, Mirela Marian, Vlad Moisoiu, Alina Tanase, Laura Pop, Anca Jurj, Ioana Berindan-Neagoe, Wilhelm-Thomas Micu, Cristina Selicean, Mihnea Zdrenghea, Kanza Arifeen, Carmen Aanei |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Oncology
medicine.medical_specialty Consensus Neoplasm Residual Chronic lymphocytic leukemia Clinical Biochemistry Antineoplastic Agents Translational research Disease Malignancy General Biochemistry Genetics and Molecular Biology 03 medical and health sciences 0302 clinical medicine hemic and lymphatic diseases Internal medicine medicine Humans Clinical significance business.industry Biochemistry (medical) High-Throughput Nucleotide Sequencing Flow Cytometry medicine.disease Leukemia Lymphocytic Chronic B-Cell Minimal residual disease body regions medicine.anatomical_structure Molecular Diagnostic Techniques 030220 oncology & carcinogenesis Prognostics Bone marrow business 030215 immunology |
| Zdroj: | Critical Reviews in Clinical Laboratory Sciences. 55:329-345 |
| ISSN: | 1549-781X 1040-8363 |
| Popis: | Chronic lymphocytic leukemia (CLL) is a malignancy defined by the accumulation of mature lymphocytes in the lymphoid tissues, bone marrow, and blood. Therapy for CLL is guided according to the Rai and Binet staging systems. Nevertheless, state-of-the-art protocols in disease monitoring, diagnostics, and prognostics for CLL are based on the assessment of minimal residual disease (MRD). MRD is internationally considered to be the level of disease that can be detected by sensitive techniques and represents incomplete treatment and a probability of disease relapse. MRD detection has been continuously improved by the quick development of both flow cytometry and molecular biology technology, as well as by next-generation sequencing. Considering that MRD detection is moving more and more from research to clinical practice, where it can be an independent prognostic marker, in this paper, we present the methodologies by which MRD is evaluated, from translational research to clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|